Posted 3/10/2024, 8:33:00 AM
Novo Nordisk Weight Loss Drug Shows Promise in Early Trial But Questions Remain
- Amycretin, Novo Nordisk's new weight loss drug candidate, showed 12% placebo-adjusted weight loss in a small 12-week phase 1 trial
- Results are promising but it's very early and trial was small (36 Japanese men)
- Safety and tolerability details were concerningly omitted
- Novo Nordisk stock is already trading at a high valuation based on high growth expectations
- It may be best to wait for a more attractive valuation before investing in Novo Nordisk
